Easy Access and Express Report Delivery Service
Table 145. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pharmacogenomics Technology (Theranostics & CDx) Product Picture Figure 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Comparison by Type (2023-2029) & (US$ Million) Figure 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type: 2022 VS 2029 Figure 7. Instrument Product Picture Figure 8. Reagents and Consumables Product Picture Figure 9. Others Product Picture Figure 10. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2029) & (US$ Million) Figure 11. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application: 2022 VS 2029 Figure 12. Tumor Product Picture Figure 13. Diabetes Product Picture Figure 14. Mental Diseases Product Picture Figure 15. Cardiovascular Diseases Product Picture Figure 16. Others Product Picture Figure 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 18. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 19. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region: 2022 VS 2029 Figure 20. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Players in 2022 Figure 21. Global Pharmacogenomics Technology (Theranostics & CDx) Players, Date of Enter into This Industry Figure 22. Global Top 5 and 10 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share by Revenue in 2022 Figure 23. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022 Figure 24. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 25. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2018-2029) Figure 26. United States Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 27. Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 29. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2018-2029) Figure 30. Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. France Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 32. U.K. Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 33. Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 34. Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 35. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 36. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 37. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2018-2029) Figure 38. China Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 39. Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 40. South Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 41. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 42. India Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 44. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 45. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2018-2029) Figure 46. Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 47. Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 48. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 49. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2018-2029) Figure 50. Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 51. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 52. UAE Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2018-2029) & (US$ Million) Figure 53. Illumina Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 54. Roche Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 55. Agilent Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 56. Abbott Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 57. Thermofisher Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 58. Qiagen Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 59. Guardant Health Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 60. MGI Tech Co., Ltd. Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 61. Amoydx Biology Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Figure 62. Genomics Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) Highlights The global Pharmacogenomics Technology (Theranostics & CDx) market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029. North American market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029. Asia-Pacific market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029. The major global companies of Pharmacogenomics Technology (Theranostics & CDx) include Illumina, Roche, Agilent, Abbott, Thermofisher, Qiagen, Guardant Health, MGI Tech Co., Ltd. and Amoydx Biology, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue. The global market for Pharmacogenomics Technology (Theranostics & CDx) in Tumor is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029. Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Instrument, which accounted for % of the global market of Pharmacogenomics Technology (Theranostics & CDx) in 2022, is expected to reach million US$ by 2029, growing at a revised CAGR of % from 2024 to 2029. Report Scope This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology (Theranostics & CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology (Theranostics & CDx). The Pharmacogenomics Technology (Theranostics & CDx) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pharmacogenomics Technology (Theranostics & CDx) market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments. The report will help the Pharmacogenomics Technology (Theranostics & CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions. Key Companies & Market Share Insights In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include: Illumina Roche Agilent Abbott Thermofisher Qiagen Guardant Health MGI Tech Co., Ltd. Amoydx Biology Genomics Product Type Insights Global markets are presented by Pharmacogenomics Technology (Theranostics & CDx) type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Pharmacogenomics Technology (Theranostics & CDx) are procured by the companies. This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029). Pharmacogenomics Technology (Theranostics & CDx) segment by Type Instrument Reagents and Consumables Others Application Insights This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029). This report also outlines the market trends of each segment and consumer behaviors impacting the Pharmacogenomics Technology (Theranostics & CDx) market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Pharmacogenomics Technology (Theranostics & CDx) market. Pharmacogenomics Technology (Theranostics & CDx) Segment by Application Tumor Diabetes Mental Diseases Cardiovascular Diseases Others Regional Outlook This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029. The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029. North America United States Canada Europe Germany France UK Italy Russia Nordic Countries Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. COVID-19 and Russia-Ukraine War Influence Analysis The readers in the section will understand how the Pharmacogenomics Technology (Theranostics & CDx) market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come. Reasons to Buy This Report This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market. This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition. This report stays updated with novel technology integration, features, and the latest developments in the market This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Pharmacogenomics Technology (Theranostics & CDx) industry. This report helps stakeholders to gain insights into which regions to target globally This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx). This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution. Core Chapters Chapter 1: Research objectives, research methods, data sources, data cross-validation; Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 6: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc. Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. Chapter 13: The main points and conclusions of the report. Frequently Asked Questions What factors will challenge the Product Name market growth? Which end-use segment will expand at the fastest CAGR in the Product Name market? Which are the emerging players in the Product Name market? How concentrated is the Product Name market? Which factors are positively contributing to the Product Name market growth? Which are the novel product innovations in the Product Name market? Which product segment will emerge as the most lucrative in the Product Name market? Which factors are increasing the competition in the Product Name market? Which are the strategic measures taken by the Product Name industry players? Which region will witness inactive growth during the forecast period? What key trends are likely to emerge in the Product Name market in the coming years?
1 Preface 1.1 Scope of Report 1.2 Reasons for Doing This Study 1.3 Research Methodology 1.4 Research Process 1.5 Data Source 1.5.1 Secondary Sources 1.5.2 Primary Sources 2 Market Overview 2.1 Product Definition 2.2 Pharmacogenomics Technology (Theranostics & CDx) by Type 2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029) 1.2.2 Instrument 1.2.3 Reagents and Consumables 1.2.4 Others 2.3 Pharmacogenomics Technology (Theranostics & CDx) by Application 2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029) 2.3.2 Tumor 2.3.3 Diabetes 2.3.4 Mental Diseases 2.3.5 Cardiovascular Diseases 2.3.6 Others 2.4 Assumptions and Limitations 3 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Type 3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2018-2023) 3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2023-2028) 4 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Application 4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2018-2023) 4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2018-2023) 5 Global Growth Trends 5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2018-2029) 5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region 5.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2018 VS 2022 VS 2029 5.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2018-2023) 5.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2024-2029) 5.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics 5.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends 5.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers 5.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges 5.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints 6 Market Competitive Landscape by Players 6.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue 6.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2018-2023) 6.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2018-2023) 6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Industry Players Ranking, 2021 VS 2022 VS 2023 6.3 Global Key Players of Pharmacogenomics Technology (Theranostics & CDx) Head office and Area Served 6.4 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application 6.5 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Date of Enter into This Industry 6.6 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI 6.7 Global Players Mergers & Acquisition 7 North America 7.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 7.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 7.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 7.5 United States 7.6 Canada 8 Europe 8.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 8.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 8.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 8.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 9 Asia-Pacific 9.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 9.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 9.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 10 Latin America 10.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 10.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 10.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 9.4 Mexico 9.5 Brazil 11 Middle East & Africa 11.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029) 11.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 11.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) 11.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 12 Players Profiled 11.1 Illumina 11.1.1 Illumina Company Detail 11.1.2 Illumina Business Overview 11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.1.5 Illumina Recent Development 11.2 Roche 11.2.1 Roche Company Detail 11.2.2 Roche Business Overview 11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.2.4 Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.2.5 Roche Recent Development 11.3 Agilent 11.3.1 Agilent Company Detail 11.3.2 Agilent Business Overview 11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.3.5 Agilent Recent Development 11.4 Abbott 11.4.1 Abbott Company Detail 11.4.2 Abbott Business Overview 11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.4.5 Abbott Recent Development 11.5 Thermofisher 11.5.1 Thermofisher Company Detail 11.5.2 Thermofisher Business Overview 11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.5.4 Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.5.5 Thermofisher Recent Development 11.6 Qiagen 11.6.1 Qiagen Company Detail 11.6.2 Qiagen Business Overview 11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.6.5 Qiagen Recent Development 11.7 Guardant Health 11.7.1 Guardant Health Company Detail 11.7.2 Guardant Health Business Overview 11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.7.5 Guardant Health Recent Development 11.8 MGI Tech Co., Ltd. 11.8.1 MGI Tech Co., Ltd. Company Detail 11.8.2 MGI Tech Co., Ltd. Business Overview 11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.8.4 MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.8.5 MGI Tech Co., Ltd. Recent Development 11.9 Amoydx Biology 11.9.1 Amoydx Biology Company Detail 11.9.2 Amoydx Biology Business Overview 11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.9.4 Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.9.5 Amoydx Biology Recent Development 11.10 Genomics 11.10.1 Genomics Company Detail 11.10.2 Genomics Business Overview 11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Introduction 11.10.4 Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) 11.10.5 Genomics Recent Development 13 Report Conclusion 14 Disclaimer